The immuno-oncological challenge of COVID-19 - Aix-Marseille Université Access content directly
Journal Articles NATURE CANCER Year : 2020

The immuno-oncological challenge of COVID-19


Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19. Zitvogel and colleagues discuss the interplay between cancer and COVID-19 with respect to patient risk and prognosis, immune responses and potential therapies.

Dates and versions

hal-03149699 , version 1 (23-02-2021)



Lisa Derosa, Clea Melenotte, Franck Griscelli, Bertrand Gachot, Aurelien Marabelle, et al.. The immuno-oncological challenge of COVID-19. NATURE CANCER, 2020, 1 (10), pp.946-964. ⟨10.1038/s43018-020-00122-3⟩. ⟨hal-03149699⟩
34 View
0 Download



Gmail Facebook X LinkedIn More